Updates - Sickle Cell Studies https://scdstudies.com Thu, 05 Dec 2024 04:04:49 +0000 en-US hourly 1 https://wordpress.org/?v=6.7.1 Patients, Scientists Agree: Automated Red Blood Cell Exchange Enhances Quality of Life in Sickle Cell Disease Patients https://scdstudies.com/updates/patients-scientists-agree-automated-red-blood-cell-exchange-enhances-quality-of-life-in-sickle-cell-disease-patients/?utm_source=rss&utm_medium=rss&utm_campaign=patients-scientists-agree-automated-red-blood-cell-exchange-enhances-quality-of-life-in-sickle-cell-disease-patients Thu, 05 Dec 2024 04:04:49 +0000 https://scdstudies.com/?post_type=updates&p=19572 A recent study found that automated red blood cell exchange (aRBCX) can greatly improve the quality of life for people with sickle cell disease (SCD). The study reviewed over 20 years of data and showed that aRBCX helps reduce hospital stays, pain-related hospital visits, and procedure times, making it a promising treatment option for SCD.

The post Patients, Scientists Agree: Automated Red Blood Cell Exchange Enhances Quality of Life in Sickle Cell Disease Patients first appeared on Sickle Cell Studies.

]]>
A recent study found that automated red blood cell exchange (aRBCX) can greatly improve the quality of life for people with sickle cell disease (SCD). The study reviewed over 20 years of data and showed that aRBCX helps reduce hospital stays, pain-related hospital visits, and procedure times, making it a promising treatment option for SCD.

The post Patients, Scientists Agree: Automated Red Blood Cell Exchange Enhances Quality of Life in Sickle Cell Disease Patients first appeared on Sickle Cell Studies.

]]>
Researchers Find Gazelle™ Hb Variant Test Offers Accuracy and Accessibility for Newborn Sickle Cell Disease Screening and Premarital Screening for Beta Thalassemia and Sickle Cell Disease https://scdstudies.com/updates/researchers-find-gazelle-hb-variant-test-offers-accuracy-and-accessibility-for-newborn-sickle-cell-disease-screening-and-premarital-screening-for-beta-thalassemia-and-sickle-cell-disease/?utm_source=rss&utm_medium=rss&utm_campaign=researchers-find-gazelle-hb-variant-test-offers-accuracy-and-accessibility-for-newborn-sickle-cell-disease-screening-and-premarital-screening-for-beta-thalassemia-and-sickle-cell-disease Fri, 18 Oct 2024 04:12:36 +0000 https://scdstudies.com/?post_type=updates&p=18890 The Gazelle™ Hb Variant Test was found to be an effective tool for accurate and affordable newborn and premarital screenings when compared with high-performance liquid chromatography (HPLC).

The post Researchers Find Gazelle™ Hb Variant Test Offers Accuracy and Accessibility for Newborn Sickle Cell Disease Screening and Premarital Screening for Beta Thalassemia and Sickle Cell Disease first appeared on Sickle Cell Studies.

]]>
The Gazelle™ Hb Variant Test was found to be an effective tool for accurate and affordable newborn and premarital screenings when compared with high-performance liquid chromatography (HPLC).

The post Researchers Find Gazelle™ Hb Variant Test Offers Accuracy and Accessibility for Newborn Sickle Cell Disease Screening and Premarital Screening for Beta Thalassemia and Sickle Cell Disease first appeared on Sickle Cell Studies.

]]>
International trial introduces another curative option for sickle cell disease https://scdstudies.com/updates/international-trial-introduces-another-curative-option-for-sickle-cell-disease/?utm_source=rss&utm_medium=rss&utm_campaign=international-trial-introduces-another-curative-option-for-sickle-cell-disease Sun, 07 Jul 2024 16:43:28 +0000 https://scdstudies.com/?post_type=updates&p=18169 An international trial has introduced a new treatment that is as safe but more affordable for sickle cell disease as the more well-known gene therapy options.

The post International trial introduces another curative option for sickle cell disease first appeared on Sickle Cell Studies.

]]>
An international trial has introduced a new treatment that is as safe but more affordable for sickle cell disease as the more well-known gene therapy options.

The post International trial introduces another curative option for sickle cell disease first appeared on Sickle Cell Studies.

]]>
Sickle Cell Disease Foundation Announces Research Collaboration with FDA on the Use of Digital Health Technologies to Bridge Health Care Gaps https://scdstudies.com/updates/https-finance-yahoo-com-news-sickle-cell-disease-foundation-announces-190900956-htmlnounces-research-collaboration-with-fda-on-the-use-of-digital-health-technologies-to-bridge-health-care-gaps/?utm_source=rss&utm_medium=rss&utm_campaign=https-finance-yahoo-com-news-sickle-cell-disease-foundation-announces-190900956-htmlnounces-research-collaboration-with-fda-on-the-use-of-digital-health-technologies-to-bridge-health-care-gaps Wed, 19 Jun 2024 01:11:02 +0000 https://scdstudies.com/?post_type=updates&p=18046 The Sickle Cell Disease Foundation (SCDF) announced a research collaboration agreement with the U.S. Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) to develop best practices for the safe and effective use of artificial intelligence (AI) and machine learning (ML) systems and digitally-derived measures that matter to patients.

The post Sickle Cell Disease Foundation Announces Research Collaboration with FDA on the Use of Digital Health Technologies to Bridge Health Care Gaps first appeared on Sickle Cell Studies.

]]>
The Sickle Cell Disease Foundation (SCDF) announced a research collaboration agreement with the U.S. Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) to develop best practices for the safe and effective use of artificial intelligence (AI) and machine learning (ML) systems and digitally-derived measures that matter to patients.

The post Sickle Cell Disease Foundation Announces Research Collaboration with FDA on the Use of Digital Health Technologies to Bridge Health Care Gaps first appeared on Sickle Cell Studies.

]]>
World’s first patient starts sickle cell gene therapy https://scdstudies.com/updates/worlds-first-patient-starts-sickle-cell-gene-therapy/?utm_source=rss&utm_medium=rss&utm_campaign=worlds-first-patient-starts-sickle-cell-gene-therapy Mon, 20 May 2024 01:43:12 +0000 https://scdstudies.com/?post_type=updates&p=17939 Kendric Cromer, a 12-year-old boy in Washington, last week became the first person in the world with sickle cell disease to begin a commercially approved gene therapy that may cure the condition, and change his whole life.

The post World’s first patient starts sickle cell gene therapy first appeared on Sickle Cell Studies.

]]>
Kendric Cromer, a 12-year-old boy in Washington, last week became the first person in the world with sickle cell disease to begin a commercially approved gene therapy that may cure the condition, and change his whole life.

The post World’s first patient starts sickle cell gene therapy first appeared on Sickle Cell Studies.

]]>
Bluebird Bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy https://scdstudies.com/updates/bluebird-bio-announces-first-outcomes-based-agreement-with-medicaid-for-sickle-cell-disease-gene-therapy/?utm_source=rss&utm_medium=rss&utm_campaign=bluebird-bio-announces-first-outcomes-based-agreement-with-medicaid-for-sickle-cell-disease-gene-therapy Mon, 11 Mar 2024 03:27:06 +0000 https://scdstudies.com/?post_type=updates&p=17448 Bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio") today announced it has signed its first Medicaid outcomes-based agreement for LYFGENIA™ (lovotibeglogene autotemcel, also known as lovo-cel) with the state of Michigan.

The post Bluebird Bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy first appeared on Sickle Cell Studies.

]]>
Bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has signed its first Medicaid outcomes-based agreement for LYFGENIA™ (lovotibeglogene autotemcel, also known as lovo-cel) with the state of Michigan.

The post Bluebird Bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy first appeared on Sickle Cell Studies.

]]>
Study Highlights Sickle Cell Disease Prevalence in Socially Disadvantaged Areas https://scdstudies.com/updates/study-highlights-sickle-cell-disease-prevalence-in-socially-disadvantaged-areas/?utm_source=rss&utm_medium=rss&utm_campaign=study-highlights-sickle-cell-disease-prevalence-in-socially-disadvantaged-areas Fri, 12 Jan 2024 05:27:57 +0000 https://scdstudies.com/?post_type=updates&p=16880 The study was presented at the annual meeting of the American Society of Hematology, underscoring the intricate needs of children with SCD and their families. It suggests that public health initiatives should be directed towards areas with higher social vulnerability to improve access to care.

The post Study Highlights Sickle Cell Disease Prevalence in Socially Disadvantaged Areas first appeared on Sickle Cell Studies.

]]>
The study was presented at the annual meeting of the American Society of Hematology, underscoring the intricate needs of children with SCD and their families. It suggests that public health initiatives should be directed towards areas with higher social vulnerability to improve access to care.

The post Study Highlights Sickle Cell Disease Prevalence in Socially Disadvantaged Areas first appeared on Sickle Cell Studies.

]]>
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease https://scdstudies.com/updates/fda-approves-first-gene-therapies-to-treat-patients-with-sickle-cell-disease/?utm_source=rss&utm_medium=rss&utm_campaign=fda-approves-first-gene-therapies-to-treat-patients-with-sickle-cell-disease Fri, 08 Dec 2023 18:49:35 +0000 https://scdstudies.com/?post_type=updates&p=16680 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.

The post FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease first appeared on Sickle Cell Studies.

]]>
Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.

The post FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease first appeared on Sickle Cell Studies.

]]>
World’s first CRISPR medicine approved in UK for sickle cell, beta thalassemia https://scdstudies.com/updates/worlds-first-crispr-medicine-approved-in-uk-for-sickle-cell-beta-thalassemia/?utm_source=rss&utm_medium=rss&utm_campaign=worlds-first-crispr-medicine-approved-in-uk-for-sickle-cell-beta-thalassemia Fri, 17 Nov 2023 23:00:05 +0000 https://scdstudies.com/?post_type=updates&p=16563 Health authorities in the U.K. on Thursday approved a new kind of medicine that uses CRISPR gene editing to treat the blood diseases sickle cell and beta thalassemia, marking it the first time a drug built with the Nobel Prize-winning technology has won regulatory clearance anywhere in the world.

The post World’s first CRISPR medicine approved in UK for sickle cell, beta thalassemia first appeared on Sickle Cell Studies.

]]>
Health authorities in the U.K. on Thursday approved a new kind of medicine that uses CRISPR gene editing to treat the blood diseases sickle cell and beta thalassemia, marking it the first time a drug built with the Nobel Prize-winning technology has won regulatory clearance anywhere in the world.

The post World’s first CRISPR medicine approved in UK for sickle cell, beta thalassemia first appeared on Sickle Cell Studies.

]]>
New treatment for sickle cell disease could soon be approved by the U.S. FDA: Dr. Peter Lin https://scdstudies.com/updates/new-treatment-for-sickle-cell-disease-could-soon-be-approved-by-the-u-s-fda-dr-peter-lin/?utm_source=rss&utm_medium=rss&utm_campaign=new-treatment-for-sickle-cell-disease-could-soon-be-approved-by-the-u-s-fda-dr-peter-lin Fri, 17 Nov 2023 22:59:27 +0000 https://scdstudies.com/?post_type=updates&p=16565 Doctor Peter Lin will tell us about a groundbreaking new treatment that uses gene-editing…with the potential to cure a serious blood disorder. And it could soon get the greenlight for use in the U-S.  

The post New treatment for sickle cell disease could soon be approved by the U.S. FDA: Dr. Peter Lin first appeared on Sickle Cell Studies.

]]>
Doctor Peter Lin will tell us about a groundbreaking new treatment that uses gene-editing…with the potential to cure a serious blood disorder. And it could soon get the greenlight for use in the U-S.

 

The post New treatment for sickle cell disease could soon be approved by the U.S. FDA: Dr. Peter Lin first appeared on Sickle Cell Studies.

]]>